Coiled Therapeutics announces next-gen formulation of brain penetrant.
Coiled Therapeutics said on Tuesday that it had developed a next-generation lipid-based softgel formulation of AO-252, its first-in-class brain-penetrant TACC3 inhibitor, with first patient dosing expected in July 2026.
Coiled Therapeutics
07 July 2026 15:38:59
Source: Sharecast
The AIM-traded company said the new formulation was designed to improve consistency and drug exposure at higher dose levels, addressing absorption limits seen with the current tablet.
It said the formulation supported its planned dose expansion cohorts in ovarian and prostate cancer, targeting enrolment of up to 30 patients by the fourth quarter.
Chief executive Sridhar Vempati said the softgel was “a key step in our dose expansion programme” and could “further strengthen AO-252's potential to deliver meaningful clinical outcomes.”
At 0859 BST, shares in Coiled Therapeutics were up 4.74% at 9.95p.
Reporting by Josh White for Sharecast.com.
See latest RNS on Investegate
N/A
ISIN:
N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes
Compare our accounts
If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
